Hormonal
Tirzepatide exposure does not significantly increase or decrease the risk of adverse cardiovascular events (myocardial infarction, coronary artery disease, heart failure, stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) in participants with type 2 diabetes or obesity compared to control groups.
For patients with T2DM or obesity, current evidence from multiple randomized trials indicates that tirzepatide does not significantly increase or decrease the risk of major cardiovascular events (like heart attack or stroke) or specific renal adverse events (like kidney stones or UTIs) compared to other treatments or placebo. While long-term safety in high-risk groups requires more data, short-to-medium term use appears safe regarding these specific outcomes.
Overall, no significant relation was observed between tirzepatide exposure and adverse cardiovascular events (RR = 0.83, 95%CI: 0.63–1.08, p = 0.16, I²=0%) or adverse renal events (RR = 1.22, 95%CI: 0.78–1.89, p = 0.39, I²=0%) compared with the control group.
Why this rating
Meta-analysis of 20 RCTs with 15,905 participants provides high statistical power, though follow-up durations were noted as short.
Source
The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials
Lishen Liu et al. · Diabetology & Metabolic Syndrome · 2025
DOI 10.1186/s13098-025-02064-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →